VCEL [NASD]
Vericel Corporation
Index- P/E- EPS (ttm)-0.24 Insider Own0.90% Shs Outstand46.98M Perf Week0.47%
Market Cap1.19B Forward P/E280.65 EPS next Y0.09 Insider Trans-4.09% Shs Float46.79M Perf Month-1.90%
Income-11.30M PEG- EPS next Q-0.07 Inst Own- Short Float17.07% Perf Quarter-32.44%
Sales157.70M P/S7.52 EPS this Y-365.40% Inst Trans1.03% Short Ratio15.86 Perf Half Y-35.63%
Book/sh3.67 P/B7.04 EPS next Y135.00% ROA-4.80% Target Price47.40 Perf Year-50.94%
Cash/sh2.19 P/C11.79 EPS next 5Y- ROE-6.90% 52W Range22.42 - 60.24 Perf YTD-34.30%
Dividend- P/FCF86.60 EPS past 5Y32.80% ROI-4.50% 52W High-57.14% Beta1.94
Dividend %- Quick Ratio6.30 Sales past 5Y23.50% Gross Margin67.50% 52W Low15.17% ATR1.32
Employees281 Current Ratio7.00 Sales Q/Q4.30% Oper. Margin-7.50% RSI (14)49.97 Volatility5.20% 5.10%
OptionableYes Debt/Eq0.00 EPS Q/Q-111.00% Profit Margin-7.10% Rel Volume0.83 Prev Close25.18
ShortableYes LT Debt/Eq0.00 EarningsMay 04 BMO Payout- Avg Volume503.73K Price25.82
Recom1.30 SMA202.90% SMA50-6.49% SMA200-30.81% Volume419,528 Change2.54%
Jan-11-21Downgrade Oppenheimer Outperform → Perform
Dec-18-20Initiated Stephens Overweight $31
Sep-17-20Initiated Truist Buy $24
Oct-09-19Initiated H.C. Wainwright Buy $19
Feb-28-19Downgrade Needham Buy → Hold
Aug-08-18Reiterated Needham Buy $15 → $14
Jul-16-18Upgrade Ladenburg Thalmann Neutral → Buy
Apr-04-18Initiated Leerink Partners Outperform $15
Mar-06-18Reiterated Needham Buy $5 → $15
Mar-06-18Downgrade Ladenburg Thalmann Buy → Neutral
Mar-05-18Reiterated BTIG Research Buy $8 → $13
Jun-21-17Initiated BTIG Research Buy $6
Mar-13-17Reiterated Needham Buy $9 → $6
Dec-22-16Initiated Piper Jaffray Overweight $6
Nov-09-16Reiterated Needham Buy $12 → $9
Apr-05-16Downgrade BofA/Merrill Buy → Neutral
Mar-11-16Upgrade Needham Hold → Buy $12
Jun-30-22 10:50AM  
May-04-22 08:30PM  
09:05AM  
07:55AM  
Apr-20-22 08:30AM  
Apr-09-22 08:07AM  
Mar-15-22 08:30AM  
Mar-01-22 08:30AM  
Feb-24-22 06:30PM  
04:45PM  
09:15AM  
07:55AM  
Feb-17-22 03:02PM  
Feb-10-22 09:00AM  
Feb-02-22 04:05PM  
Jan-25-22 09:38PM  
Jan-04-22 08:30AM  
Dec-17-21 11:38AM  
Dec-13-21 04:38PM  
Nov-11-21 08:30AM  
Nov-09-21 08:01PM  
08:55AM  
07:40AM  
Nov-02-21 03:02PM  
Oct-29-21 11:11AM  
Oct-21-21 08:30AM  
Oct-13-21 06:25AM  
Sep-29-21 12:33PM  
Sep-08-21 08:30AM  
Sep-07-21 08:30AM  
Aug-31-21 09:15AM  
Aug-04-21 10:01PM  
09:45AM  
08:00AM  
Jul-28-21 03:03PM  
Jul-26-21 10:59AM  
Jul-22-21 08:00AM  
Jul-21-21 08:30AM  
Jul-19-21 09:54AM  
06:20AM  
Jul-18-21 10:50AM  
Jul-15-21 08:15PM  
Jul-07-21 08:23PM  
08:30AM  
Jul-05-21 10:06PM  
Jul-03-21 10:00PM  
Jul-01-21 06:01AM  
Jun-29-21 10:15PM  
04:18PM  
04:10PM  
09:23AM  
08:45AM  
08:45AM  
Jun-09-21 09:00AM  
Jun-02-21 08:30AM  
May-13-21 08:30AM  
May-06-21 03:31AM  
May-05-21 08:35AM  
07:00AM  
06:45AM  
Apr-28-21 12:34PM  
Apr-23-21 10:36PM  
Apr-21-21 08:30AM  
Apr-09-21 09:24AM  
Mar-18-21 05:40PM  
08:16AM  
Mar-17-21 06:00PM  
Mar-10-21 05:50PM  
08:30AM  
Mar-08-21 07:43AM  
Mar-04-21 06:33AM  
Mar-02-21 08:30AM  
Feb-24-21 02:01PM  
08:50AM  
08:00AM  
06:30AM  
Feb-22-21 08:30AM  
Feb-16-21 08:30AM  
Feb-12-21 08:30AM  
Feb-10-21 08:00AM  
Feb-04-21 12:00PM  
Feb-01-21 09:42AM  
05:20AM  
Jan-25-21 08:30AM  
Jan-11-21 07:15AM  
Jan-08-21 08:30AM  
Jan-07-21 08:30AM  
07:05AM  
Jan-06-21 12:48PM  
Dec-19-20 10:10PM  
Dec-18-20 08:30AM  
Nov-09-20 11:44AM  
Nov-05-20 10:32PM  
08:00AM  
Nov-03-20 09:43AM  
05:54AM  
Nov-02-20 08:30AM  
06:40AM  
Oct-30-20 03:54PM  
Oct-29-20 11:30AM  
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILMAN STEVEN CDirectorApr 29Sale30.9490027,8465,200May 02 04:07 PM
Hopper Jonathan MarkChief Medical OfficerMar 01Option Exercise14.4720,000289,50055,914Mar 03 04:06 PM
Hopper Jonathan MarkChief Medical OfficerMar 01Sale41.4316,738693,43145,914Mar 03 04:06 PM
Hopper Jonathan MarkChief Medical OfficerFeb 19Option Exercise0.001,750046,644Feb 22 04:11 PM
Halpin MichaelChief Operating OfficerFeb 19Option Exercise0.002,812011,495Feb 22 04:09 PM
Flynn Sean C.VP, General CounselFeb 19Option Exercise0.001,75004,314Feb 22 04:08 PM
Colangelo DominickPresident and CEOFeb 19Option Exercise0.008,9370160,307Feb 22 04:07 PM
Hopper Jonathan MarkChief Medical OfficerFeb 11Option Exercise0.001,625045,669Feb 15 04:52 PM
Halpin MichaelChief Operating OfficerFeb 11Option Exercise0.003,500010,247Feb 15 04:51 PM
Colangelo DominickPresident and CEOFeb 11Option Exercise0.007,5000154,621Feb 15 04:48 PM
Hopper Jonathan MarkChief Medical OfficerFeb 06Option Exercise0.00650044,354Feb 08 05:04 PM
Halpin MichaelChief Operating OfficerFeb 06Option Exercise0.001,87507,678Feb 08 05:02 PM
Colangelo DominickPresident and CEOFeb 06Option Exercise0.006,9370150,170Feb 08 05:01 PM
Mara Joseph Anthony JrChief Financial OfficerDec 31Option Exercise0.004,000012,787Jan 04 04:05 PM
Hopper Jonathan MarkChief Medical OfficerDec 22Option Exercise13.9619,000265,15049,428Dec 22 06:54 PM
Hopper Jonathan MarkChief Medical OfficerDec 22Sale40.1114,881596,93039,428Dec 22 06:54 PM
Hopper Jonathan MarkChief Medical OfficerDec 20Option Exercise10.951,00010,95040,428Dec 22 06:54 PM
Hopper Jonathan MarkChief Medical OfficerDec 20Sale40.001,00040,00039,428Dec 22 06:54 PM
GILMAN STEVEN CDirectorNov 29Option Exercise3.745,00018,7008,500Dec 01 04:07 PM
GILMAN STEVEN CDirectorNov 29Sale39.175,000195,8553,500Dec 01 04:07 PM
GILMAN STEVEN CDirectorOct 27Option Exercise3.745,00018,7008,500Oct 28 04:12 PM
GILMAN STEVEN CDirectorOct 27Sale50.575,000252,8703,500Oct 28 04:12 PM
Halpin MichaelChief Operating OfficerOct 26Option Exercise2.6510,00026,50015,696Oct 28 04:09 PM
Halpin MichaelChief Operating OfficerOct 26Sale50.5710,000505,6895,696Oct 28 04:09 PM
GILMAN STEVEN CDirectorSep 30Option Exercise3.745,00018,7008,500Oct 01 04:12 PM
Mara Joseph Anthony JrChief Financial OfficerSep 30Option Exercise0.004,00009,894Oct 01 04:13 PM
GILMAN STEVEN CDirectorSep 30Sale48.855,000244,2553,500Oct 01 04:12 PM
Flynn Sean C.VP, General CounselAug 27Option Exercise16.257,200117,0009,619Aug 31 04:10 PM
Flynn Sean C.VP, General CounselAug 27Sale55.117,200396,7602,419Aug 31 04:10 PM
Halpin MichaelChief Operating OfficerAug 16Option Exercise2.6515,00039,75020,623Aug 18 04:05 PM
Halpin MichaelChief Operating OfficerAug 16Sale48.0315,000720,4805,623Aug 18 04:05 PM
Flynn Sean C.VP, General CounselJul 21Option Exercise16.252,80045,5005,219Jul 23 04:04 PM
Flynn Sean C.VP, General CounselJul 21Sale55.012,800154,0282,419Jul 23 04:04 PM
Flynn Sean C.VP, General CounselJul 15Option Exercise16.2510,000162,50012,419Jul 16 04:07 PM
Flynn Sean C.VP, General CounselJul 15Sale51.1810,000511,7862,419Jul 16 04:07 PM
Halpin MichaelChief Operating OfficerJul 12Option Exercise2.6520,00053,00025,623Jul 14 04:13 PM
Halpin MichaelChief Operating OfficerJul 12Sale53.5420,0001,070,8765,623Jul 14 04:13 PM